Methotrexate treatment hampers induction of vaccine-specific CD4 T cell responses in patients with IMID

Autor: Sander W Tas, Joep Killestein, Joost Raaphorst, Taco W Kuijpers, Alexandre E Voskuyl, Gertjan Wolbink, Theo Rispens, Anneke J van der Kooi, Anja Ten Brinke, Karina de Leeuw, Abraham Rutgers, Juan J Garcia-Vallejo, Frederike J Bemelman, YK Onno Teng, Phyllis I Spuls, Mark Löwenberg, Jelle de Wit, Diane van der Woude, Marcel W Bekkenk, Luuk Wieske, Esther Brusse, Laura Boekel, Filip Eftimov, Eileen W Stalman, Maurice Steenhuis, Sofie Keijzer, Olvi Cristianawati, Koos P J van Dam, Adriaan G Volkers, Annelie H Musters, Nicoline F Post, Angela L Bosma, Marc L Hilhorst, Yosta Vegting, Bo Broens, Barbara Horváth, Annabel M Ruiter, Matthias H Busch, Dirk Jan Hijnen, Niels J M Verstegen, Pieter A van Doorn, Jan JGM Verschuuren, Laura Y L Kummer, Ruth R Hagen, Christine Kreher, Lisan H Kuijper, Mariël C Duurland, Veronique A L Konijn, Carolien E van de Sandt, Laura Fernández Blanco, Amélie Bos, Charlotte Menage, Tineke Jorritsma, Jet van den Dijssel, Rivka de Jongh, Tom Ashhurst, Marit J van Gils, Mathieu Claireaux, Sija Marieke van Ham, Renée CF van Allaart, Adája E Baars, George Elias, Cécile ACM van Els, H Stephan Goedee, Geert RAM D’Haens, Papay BP Jallah, Elham S Mirfazeli, Jim BD Keijser, Lotte van Ouwerkerk, Pieter van Paassen, Agner R Parra Sanchez, W Ludo van der Pol, Corine RG Schreurs, R Bart Takkenberg, Koos AH Zwinderman

Publikováno v: RMD Open, Vol 10, Iss 4 (2024)

Objectives Methotrexate (MTX) is one of the most commonly used medications to treat rheumatoid arthritis (RA). However, the effect of MTX treatment on cellular immune responses remains incompletely understood. This raises concerns about the vulnerabi

Externí odkaz: https://doaj.org/article/afff65e4600e4deabe9d42545d2637c0

Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma

Autor: Diane van der Woude, Theo Rispens, Catharina M Korse, Sjoerd H van der Burg, Ellen Kapiteijn, John B A G Haanen, Winan J van Houdt, Els M E Verdegaal, Marij J P Welters, Jessica S W Borgers, Tineke J van Wesemael, Johannes V van Thienen, Kyra A Gelderman, Dirk J A R Moes

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 12, Iss 6 (2024)

Introduction Treatment with the immune checkpoint inhibitor anti-programmed cell death protein-1 (PD-1) often causes immune-related adverse events (irAEs). Since irAEs resemble autoimmune diseases, autoantibodies might play a role and could potential

Externí odkaz: https://doaj.org/article/9616b7f6fe8b499baab93acfee17c709

Concentrations of subcutaneously administered belimumab in human breast milk of a woman with systemic lupus erythematosus: a case report

Autor: Alexandre E Voskuyl, Theo Rispens, Marjon A de Boer, Mirjam M van Weissenbruch, Irene E M Bultink, Birgit S Blomjous, Koen C J Laan

Publikováno v: Lupus Science and Medicine, Vol 11, Iss 1 (2024)

Externí odkaz: https://doaj.org/article/f239d576e48e4f5e8415f32f44b342d2

Longitudinal rheumatoid factor autoantibody responses after SARS-CoV-2 vaccination or infection

Autor: Sofie Keijzer, Nienke Oskam, Pleuni Ooijevaar-de Heer, Maurice Steenhuis, Jim B.D. Keijser, Luuk Wieske, Koos P.J. van Dam, Eileen W. Stalman, Laura Y.L. Kummer, Laura Boekel, Taco W. Kuijpers, Anja ten Brinke, S. Marieke van Ham, Filip Eftimov, Sander W. Tas, Gerrit J. Wolbink, Theo Rispens

Publikováno v: Frontiers in Immunology, Vol 15 (2024)

BackgroundRheumatoid factors (RFs) are autoantibodies that target the Fc region of IgG, and are found in patients with rheumatic diseases as well as in the healthy population. Many studies suggest that an immune trigger may (transiently) elicit RF re

Externí odkaz: https://doaj.org/article/f23a6c0fb19b45e796cbf67b6dbbd340

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.